Radioiodine (131I) has been used to treat differentiated thyroid carcinoma for the past fifty
years. The activity administered remains empirical and most clinicians prescribe a fixed …

Every effort has been made to ensure that drug usage and other information are presented
accurately; however, the ultimate responsibility rests with the prescribing physician …

The treatment of differentiated thyroid cancer continues to move away from a 'one size fits
all'approach to a process of tailored therapeutic decision-making that incorporates disease …

Background Level 1 evidence from randomised controlled studies in thyroid cancer
management is generally lacking. Therefore, the published US [

The standard treatment for the ablation of thyroid remnant tissue following surgery as well as
for the treatment of iodine avid metastases in patients suffering from differentiated thyroid …

Within the UK, standard therapy activities of 1.1 GBq and 3.7 MBq of I-131 are typically given
to low and high risk ablation patients respectively, while 5.5 GBq is administered for repeat …

UK thyroid cancer survival figures are some of the worst in Europe. The 2002 British Thyroid
Association (BTA) guidelines aimed to address this and recommended slightly more …

Differentiated thyroid cancer (DTC) is the most common endocrine malignancy. It usually
has a comparatively benign course. If properly executed, radioiodine therapy can provide an …

Objectives: Describe the mechanism of action of RAI in the treatment of thyroid
malignancies. Outline RAI treatment indications and contraindications in thyroid cancers …

The incidence of thyroid cancer has increased exponentially around the world (mostly
papillary thyroid carcinoma). This growth may reflect the combined effects of increased …